Venous Thromboembolism Risk Stratification and Prophylaxis in Multiple Myeloma
DOI:
https://doi.org/10.32635/2176-9745.RBC.2024v70n1.4440Keywords:
Multiple Myeloma, Thromboembolism, Disease PreventionAbstract
Thrombosis is challenging in multiple myeloma. Advances of therapeutic arsenal for this cancer increased survival but at the same time led to the incidence of thrombotic events with impacts on morbidity and mortality. In addition, the epidemiological profile of this population favors the coexistence of cardiovascular disease sharing thrombogenic physiopathological mechanisms with cancer. Regardless of the use of anticoagulants and platelet antiaggregant, the ideal strategy for prophylaxis remains obscure and the challenge goes beyond the standardization of risk evaluation and anticoagulant therapy. This article attempted to present the state-of-art about the theme with the objective to discuss thromboprophylaxis in multiple myeloma, highlighting the approach to cardiovascular disease as part of this strategy.
Downloads
References
Gervaso L, Dave H. Venous and arterial thromboembolism in patients with cancer: state-of-the-art review. JACC Cardio Oncol. 2021;3(2):173190. doi: https://doi.org/10.1016/j.jaccao.2021.03.001 DOI: https://doi.org/10.1016/j.jaccao.2021.03.001
Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist. 2017;22:199-207.
Renni M. Cerqueira MH, Trugilho IA, et al. Mecanismos do tromboembolismo venoso no câncer: uma revisão da literatura. J Vasc Bras. 2017;16(4):308-13. doi: https://doi.org/10.1590/1677-5449.007817 DOI: https://doi.org/10.1590/1677-5449.007817
Fotiou D, Gavriatopoulou M. Multiple myeloma and thrombosis: prophylaxis and risk prediction tools. Cancers (Basel). 2020;12(1):191. DOI: https://doi.org/10.3390/cancers12010191
Covut F, Ahmed R. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. Br J Haematol. 2021;193(6):1213-9. DOI: https://doi.org/10.1111/bjh.17505
Stefano V, Larocca A. Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. a consensus-based position paper from an ad hoc expert panel. Haematologica. 2022;107(11):2536-47 DOI: https://doi.org/10.3324/haematol.2022.280893
Fotiou D, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. Updates on thrombotic events associated with multiple myeloma. Expert Rev Hematol. 2019;12(5):355-65. doi: https://doi.org/10.1080/17474086.2019.1604214 DOI: https://doi.org/10.1080/17474086.2019.1604214
Chung I, Lip GY. Virchow’s triad revisited: blood constituents. Pathophysiol Haemost Thromb. 2003;33(5-6):449-54. doi: https://doi.org/10.1159/000083844 DOI: https://doi.org/10.1159/000083844
Camilli M, Lannaccone G, La Vecchia G. Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases. Expert Review of Hematol. 2021;14(6)537-46. doi: https://doi.org/10.1080/17474086.2021.1943353 DOI: https://doi.org/10.1080/17474086.2021.1943353
Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist. 2017;22(2):199-207. doi: https://doi.org/10.1634/theoncologist.2016-0214 DOI: https://doi.org/10.1634/theoncologist.2016-0214
Nicol M, Siguret V, Vergaro G, et al Thromboembolism and bleeding in systemic amyloidosis: a review. ESC Heart Failure. 2022;9(1):11-20. doi: https://doi.org/10.1002/ehf2.13701 DOI: https://doi.org/10.1002/ehf2.13701
Chakraborty R, Bin Riaz I, Malik SU, et al. Venous thromboembolism risk with contemporary lenalidomidebased regimens despite thromboprophylaxis in multiple myeloma: systematic review and meta-analysis. Cancer. 2020;126(8):1640-50. doi: https://doi.org/10.1002%2Fcncr.32682 DOI: https://doi.org/10.1002/cncr.32682
Lyon AR, López-Fernández T, Couch LS. ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology
Society (IC-OS). Eur Heart J. 2022;43(41):4229-361. doi: https://doi.org/10.1093/eurheartj/ehac244 DOI: https://doi.org/10.1093/eurheartj/ehac244
Lapietra G, Serrao A. Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going? J Thromb Thrombolysis. 2021;52(2):584-9. DOI: https://doi.org/10.1007/s11239-020-02354-7
Terpos E, Kleber M, Engelhardt M, et al. European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254-66. doi: https://doi.org/10.3324/haematol.2014.117176 DOI: https://doi.org/10.3324/haematol.2014.117176
Bradbury C, Craig Z, Cook G, et al. Thrombosis in patients with myeloma treated in the myeloma ix and myeloma xi phase 3 randomized controlled trials. Blood. 2020;136(9):1091-104. doi: https://doi.org/10.1182/blood.2020005125 DOI: https://doi.org/10.1182/blood.2020005125
Rubinstein SM, Tuchman SA. Thrombosis in the modern era of multiple myeloma. Blood. 2020;136(9):1019-21. DOI: https://doi.org/10.1182/blood.2020006648
Published
How to Cite
Issue
Section
License
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
This work is licensed under a Creative Commons Attribution 4.0 International License.
